Skip to main content

Developing Countries: Tuberculosis

Volume 508: debated on Wednesday 24 March 2010

To ask the Secretary of State for International Development what steps his Department is taking to seek to ensure adequate levels of funding for research and development of new drugs, diagnostics and vaccines to reduce the number of cases of MDR and XDR tuberculosis in developing countries. (323670)

The Department for International Development (DFID) is providing £24.5 million, from 2006 to 2013, to the Global Alliance for Tuberculosis Drug Development (TBA). The TBA is a not-for-profit public private partnership developing new tuberculosis drugs that will shorten treatment, be effective against susceptible and resistant strains of tuberculosis and be compatible with antiretroviral therapies for those patients who are co-infected with HIV and tuberculosis.

DFID is also providing £12 million to the Tropical Disease Research special programme at WHO, from 2008 to 2013. The work of this programme has included accelerating the development of new diagnostics, including tuberculosis, and gaining evidence about how best to combine therapy for HIV and tuberculosis co-infection.